Juhe Bio Announces Over RMB 100 Million Series B Financing Led by Prosperity7 Ventures to Advance Women's Health Innovations

VCBeat has learned that on December 27, 2023, Beijing/Shenzhen – Shenzhen Shunshi Juhe Biotechnology Co., Ltd. (hereinafter referred to as “Juhe Biotech”), a technology innovation enterprise centered on women’s health, announced the successful completion of its Series B financing round, exceeding RMB 100 million. The round was led by Prosperity7 Ventures, the diversified growth fund under Aramco Ventures, with additional investment from existing shareholder Sunland Capital. The continued support from existing shareholders and the participation of new investors demonstrate the market’s strong confidence in and high expectations for Juhe Biotech.

Since its inception, Juhe Bio has remained committed to a path of technological innovation, achieving significant translational breakthroughs in key areas of diagnostic testing for women’s health conditions. The capital raised in this round will strongly propel the company’s global business expansion, product development, regulatory registration and filings, as well as growth in public health management and consumer healthcare segments, delivering efficient solutions to a broad user base.

In the field of women's health, Juhui Biotechnology has successfully launched methylation detection products for early screening of gynecological tumors and female reproductive microecology detection products, injecting new vitality into clinical practice and applications in this field. Its core product, He Gong Kang CISCER® (NMPA Registration No. 20233400253), was approved for market launch by China's National Medical Products Administration (NMPA) in March this year. The company also held a product launch and multicenter data release event at the 9th Chinese Society of Colposcopy and Cervical Pathology (CSCCP) Congress.

At the conference, the honorary presidium, led by renowned obstetrics and gynecology experts Academician Lang Jinghe and Professor Wei Lihui, along with multiple distinguished industry experts, highly praised the clinical research findings of this product. Notably, the dual-target genes selected for Hegongkang CISCER® have been included in the "Blue Book on Standardized Tertiary Prevention of Cervical Cancer in China," which recommends their application in various scenarios for the diagnosis and treatment of cervical cancer. Meanwhile, Juhe Biotechnology is further strengthening its layout for early screening and diagnosis of gynecological tumors. Its endometrial cancer screening product (Hekouan CISENDO), with an investment of nearly RMB 100 million, has completed clinical trials, while its ovarian cancer methylation product (Heweiyi CISOVA) is currently undergoing clinical trials.

In addition, Juhue Biology is actively engaged in clinical translational research, having successfully conducted three nationwide multicenter studies involving tens of thousands of participants, multiple provincial-level studies, and one China-Europe cross-national study. The company is currently collaborating with leading institutions in Southeast Asia, Europe, and other regions, actively carrying out academic and market promotion activities to further expand its global technological influence.

This round of financing will enable Juhe Biotech to expand its global market presence, diversify its product portfolio, and further explore the potential of its technologies in the fields of public health and consumer healthcare. Furthermore, Juhe Biotech is committed to exploring and developing additional technologies and products related to women’s health management, aiming to meet the diverse health needs of women worldwide.

Juhe Bio’s Series B financing not only demonstrates the market’s confidence in its future growth, but also signals its bold strategic expansion and development in the global women’s health sector, making its future prospects highly promising.

Dr. Pei Liu, Founder of Juhe Biostated: “We are deeply grateful to both new and existing shareholders for their recognition and strong support of the company. Juhe Bio will remain true to its original mission, continuously enriching and developing an innovative pipeline focused on gynecological diseases to address current unmet clinical needs, benefit patients, and contribute to the pharmaceutical industry. We are honored to announce the successful completion of this pivotal financing round, which underscores the market’s firm confidence in our technology and vision. The proceeds from this financing will not only support further advancement of our product R&D but also facilitate our expansion in domestic and international markets, particularly in building out our consumer healthcare business segment.”

Aysar Tayeb, Executive Director and Managing Director of Prosperity7 Ventures, the lead investor in this round of financingstated: “We are delighted to lead the Series B financing round for Juhe Bio. Prosperity7 Ventures is committed to supporting impactful enterprises, and Juhe Bio is precisely such a company, having achieved remarkable success in early disease detection. As Juhe Bio accelerates its global market expansion and focuses on broadly improving women’s health, we believe the company will achieve even greater success.”

Gu Shenghan, Executive Director of Sunland Capitalstated: “Since Sunland’s initial investment in Juhe during its early startup phase, we have witnessed the founding team’s exceptional execution capabilities. Deeply rooted in gynecology, the company has continuously launched industry-leading innovative products to address various unmet diagnostic needs in this field. Throughout this process, it has strictly adhered to high-standard clinical research pathways, laying a solid foundation for product performance and large-scale clinical application. As the company’s products are successively brought to market, we are pleased to see Juhe filling current gaps in early screening and diagnosis for multiple gynecological conditions. Sunland’s strategic investments in gynecology and reproductive health are enabling more patients to benefit from the clinical application of domestically produced innovative technologies and products.”

Juhue Biotech is a high-tech enterprise driven by innovative technology and dedicated to promoting health. As a pioneer in the early diagnosis of gynecological tumors, Juhue Biotech has developed early diagnostic products for cervical cancer, endometrial cancer, ovarian cancer, and other gynecological malignancies, leveraging its proprietary technologies and patent-protected biomarkers, thereby filling gaps in women’s healthcare. Headquartered at the Daxing Biomedical Base in Beijing, the company focuses on the research and development, production, and sales of early diagnostic products for gynecological tumors as well as related automated detection equipment. Juhue Biotech also possesses leading methylation detection technology and holds intellectual property rights for multiple biomarkers.

Prosperity7 Ventures (P7) is a diversified growth fund under Aramco Ventures, the venture capital arm of Saudi Aramco, the world’s leading integrated energy and chemicals company. The name “Prosperity7” refers to the first oil well struck in Saudi Arabia, which was also the seventh well drilled in the country and is known as the “Well of Prosperity.” Building on this pioneering legacy, P7 takes a long-term view in making global investments that drive disruptive technological advancements and business model transformations, aiming to foster shared prosperity and positive impact worldwide. With $1 billion in assets under management, P7 has investment teams based in Saudi Arabia, the United States, and China. It focuses on investing in highly scalable startups in the Chinese and U.S. markets, spanning sectors such as enterprise IT, fintech, artificial intelligence, B2B, consumer technology, and health tech.